These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34126710)

  • 1. [To positively deal with the challenges brought by the diagnosis and treatment of systemic light chain amyloidosis].
    Huang XH; Liu ZH
    Zhonghua Yi Xue Za Zhi; 2021 Jun; 101(22):1631-1634. PubMed ID: 34126710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I Approach Light Chain Amyloidosis.
    Chowdhury RB; Leung N
    G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [AL Amyloidosis].
    Ueda M
    Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
    Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
    Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation.
    Dima D; Mazzoni S; Anwer F; Khouri J; Samaras C; Valent J; Williams L
    JCO Oncol Pract; 2023 May; 19(5):265-275. PubMed ID: 36854070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroperitoneal involvement with light chain amyloidosis- case series and literature review.
    Vaxman I; Visram A; Pasvolsky O; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Kyle R; Kapoor P; Leung N; Gonsalves W; Kourelis T; Warsame R; Gertz M
    Leuk Lymphoma; 2021 Feb; 62(2):316-322. PubMed ID: 33118418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [AL amyloidosis, from diagnosis to treatment].
    Villesuzanne C; Jaccard A; Nicol M
    Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to Suspect a Diagnosis of Amyloidosis.
    Vaxman I; Gertz M
    Acta Haematol; 2020; 143(4):304-311. PubMed ID: 32340017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized Lymph Node Light Chain Amyloidosis.
    Yamamoto A; Fujii N; Obika M; Yamashita T; Otsuka F
    Intern Med; 2020 Oct; 59(19):2415-2418. PubMed ID: 32611959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis for Chinese patients with light chain amyloidosis: a scoping review.
    Chen M; Liu J; Wang X; Cao X; Gao X; Xu L; Liu W; Pi J; Wang B; Li J
    Ann Med; 2023 Dec; 55(1):2227425. PubMed ID: 37387123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
    Basset M; Nuvolone M; Palladini G; Merlini G
    Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bad players in AL amyloidosis in the current era of treatment.
    Kreiniz N; Gertz MA
    Expert Rev Hematol; 2023 Jan; 16(1):33-49. PubMed ID: 36620914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic amyloidosis: moving into the spotlight.
    Cohen OC; Wechalekar AD
    Leukemia; 2020 May; 34(5):1215-1228. PubMed ID: 32269317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of gastroduodenal biopsy in the differential diagnosis of systemic AH amyloidosis from systemic AL amyloidosis.
    Ichimata S; Kobayashi M; Shimojo H; Katoh N; Yazaki M; Kanno H
    Histopathology; 2018 Aug; 73(2):230-239. PubMed ID: 29660165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of the elderly patient with AL amyloidosis.
    Nuvolone M; Milani P; Palladini G; Merlini G
    Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous light chain amyloidosis with multiple myeloma: A concise review.
    Andrei M; Wang JC
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):71-81. PubMed ID: 30261180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.
    Baumgart JV; Stuhlmann-Laeisz C; Hegenbart U; Nattenmüller J; Schönland S; Krüger S; Behrens HM; Röcken C
    Virchows Arch; 2018 Nov; 473(5):627-637. PubMed ID: 30136180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in the Diagnosis and Management of AL Amyloidosis.
    Cook J; Muchtar E; Warsame R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):155-167. PubMed ID: 32394186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.